96 related articles for article (PubMed ID: 27769273)
1. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
Pulford DJ; Harter P; Floquet A; Barrett C; Suh DH; Friedlander M; Arranz JA; Hasegawa K; Tada H; Vuylsteke P; Mirza MR; Donadello N; Scambia G; Johnson T; Cox C; Chan JK; Imhof M; Herzog TJ; Calvert P; Wimberger P; Berton-Rigaud D; Lim MC; Elser G; Xu CF; du Bois A
BMC Med Ethics; 2016 Oct; 17(1):63. PubMed ID: 27769273
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F
Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
6. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
7. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
[TBL] [Abstract][Full Text] [Related]
8. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer following ovarian cancer in BRCA mutation carriers.
Gangi A; Cass I; Paik D; Barmparas G; Karlan B; Dang C; Li A; Walsh C; Rimel BJ; Amersi FF
JAMA Surg; 2014 Dec; 149(12):1306-13. PubMed ID: 25372568
[TBL] [Abstract][Full Text] [Related]
10. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
Kwiatkowski F; Arbre M; Bidet Y; Laquet C; Uhrhammer N; Bignon YJ
PLoS One; 2015; 10(6):e0127363. PubMed ID: 26047126
[TBL] [Abstract][Full Text] [Related]
11. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND
J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
[No Abstract] [Full Text] [Related]
12. Psychological distress related to BRCA testing in ovarian cancer patients.
Bjørnslett M; Dahl AA; Sørebø Ø; Dørum A
Fam Cancer; 2015 Dec; 14(4):495-504. PubMed ID: 25980896
[TBL] [Abstract][Full Text] [Related]
13. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
14. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
15. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
16. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
Krivokuca A; Dobricic J; Brankovic-Magic M
J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
[TBL] [Abstract][Full Text] [Related]
17. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
Pinto C; Bella MA; Capoluongo E; Carrera P; Clemente C; Colombo N; Cortesi L; De Rosa G; Fenizia F; Genuardi M; Gori S; Guarneri V; Marchetti A; Marchetti P; Normanno N; Pasini B; Pignata S; Radice P; Ricevuto E; Russo A; Tagliaferri P; Tassone P; Truini M; Varesco L
Future Oncol; 2016 Sep; 12(18):2071-5. PubMed ID: 27241581
[No Abstract] [Full Text] [Related]
19. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.
Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S
Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
